Ali Behbahani, Director at Adaptimmune Therapeutics PLC (ADAP), bought 7,500,000 shares at $0.67 ($5.0M) on 2020-01-24, disclosed to the SEC on 2020-01-28.
Open-market purchase of $5.0M ADAP by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Nothing distinguishes this filing.
| Filing → |
| ADAP | SELL | 2025-08-19 | $342K | — | Filing → |
| MBX | BUY | 2024-09-17 | $8.0M | — | Filing → |
| SVRA | BUY | 2023-07-19 | $1000K | — | Filing → |